Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. https://doi.org/10.1002/hep.28431. (PMID: 26707365).

Article  PubMed  Google Scholar 

Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–85.

Article  CAS  PubMed  Google Scholar 

European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–402. https://doi.org/10.1016/j.jhep.2015.11.004.

Article  Google Scholar 

Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–9. https://doi.org/10.1016/j.jhep.2020.03.039. (PMID: 32278004).

Article  PubMed  Google Scholar 

Eslam M, Sanyal AJ, George J, International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999-2014.e1. https://doi.org/10.1053/j.gastro.2019.11.312. (PMID: 32044314).

Article  CAS  PubMed  Google Scholar 

Kleiner DE, Brunt EM, Wilson LA, et al. Nonalcoholic steatohepatitis clinical research network. Association of histologic disease activity with progression of nonalcoholic fatty liver disease. JAMA Netw Open. 2019;2(10): e1912565. https://doi.org/10.1001/jamanetworkopen.2019.12565. (PMID: 31584681; PMCID: PMC6784786).

Article  PubMed  PubMed Central  Google Scholar 

De A, Duseja A. Natural history of simple steatosis or nonalcoholic fatty liver. J Clin Exp Hepatol. 2020;10(3):255–62. https://doi.org/10.1016/j.jceh.2019.09.005.PMID:32405182;PMCID:PMC7212297.

Article  PubMed  Google Scholar 

McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62(5):1148–55. https://doi.org/10.1016/j.jhep.2014.11.034. (PMID: 25477264).

Article  PubMed  Google Scholar 

Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643-54.e9. https://doi.org/10.1016/j.cgh.2014.04.014. (PMID: 24768810; PMCID: PMC4208976).

Article  PubMed  Google Scholar 

Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65:589–600.

Article  PubMed  Google Scholar 

Kleiner DE, Brunt EM, Van Natta M, et al. Nonalcoholic steatohepatitis clinical research network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21. https://doi.org/10.1002/hep.20701. (PMID: 15915461).

Article  PubMed  Google Scholar 

Kawada N, Imanaka K, Kawaguchi T, et al. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J Gastroenterol. 2009;44(12):1190–4. https://doi.org/10.1007/s00535-009-0112-0. (PMID: 19672551).

Article  PubMed  Google Scholar 

Younossi Z, Stepanova M, Ong JP, et al. Global nonalcoholic steatohepatitis council. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2019;17(4):748–7553. https://doi.org/10.1016/j.cgh.2018.05.057. (PMID: 29908364).

Article  PubMed  Google Scholar 

Musso G, Gambino R, Tabibian JH, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014;11(7): e1001680. https://doi.org/10.1371/journal.pmed.1001680.PMID:25050550;PMCID:PMC4106719.

Article  PubMed  PubMed Central  Google Scholar 

Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65(5):1557–65. https://doi.org/10.1002/hep.29085. (PMID: 28130788; PMCID: PMC5397356).

Article  CAS  PubMed  Google Scholar 

Mouries J, Brescia P, Silvestri A, et al. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. J Hepatol. 2019;71(6):1216–28. https://doi.org/10.1016/j.jhep.2019.08.005. (PMID: 31419514; PMCID: PMC6880766).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389-97.e10. https://doi.org/10.1053/j.gastro.2015.04.043. (PMID: 25935633; PMCID: PMC4516664).

Article  PubMed  Google Scholar 

Hagström H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67(6):1265–73. https://doi.org/10.1016/j.jhep.2017.07.027. (PMID: 28803953).

Article  PubMed  Google Scholar 

Taylor RS, Taylor RJ, Bayliss S, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology. 2020;158(6):1611-1625.e12. https://doi.org/10.1053/j.gastro.2020.01.043. (PMID: 32027911).

Article  CAS  PubMed  Google Scholar 

Yamamichi N, Shimamoto T, Okushin K, et al. Fibrosis-4 index efficiently predicts chronic hepatitis and liver cirrhosis development based on a large-scale data of general population in Japan. Sci Rep. 2022;12(1):20357. https://doi.org/10.1038/s41598-022-24910-2. (PMID: 36437271; PMCID: PMC9701772).

Article  CAS  PubMed  PubMed Central  Google Scholar 

McPherson S, Stewart SF, Henderson E, et al. Simple non-invasive fibrosis scoring systems canreliably exclude advanced fibrosis in patientswith non-alcoholic fatty liver disease. Gut. 2010;59:1265–9.

Article  PubMed  Google Scholar 

Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67(1):328–57. https://doi.org/10.1002/hep.29367. (PMID: 28714183).

Article  PubMed  Google Scholar 

Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology. 2007;46(1):32–6. https://doi.org/10.1002/hep.21669. (PMID: 17567829).

Article  CAS  PubMed  Google Scholar 

Mózes FE, Lee JA, Selvaraj EA, LITMUS Investigators, et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut. 2022;71(5):1006–19. https://doi.org/10.1136/gutjnl-2021-324243. (PMID: 34001645; PMCID: PMC8995830).

Article  PubMed  Google Scholar 

Treeprasertsuk S, Björnsson E, Enders F, Suwanwalaikorn S, Lindor KD. NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol. 2013;19(8):1219–29. https://doi.org/10.3748/wjg.v19.i8.1219.PMID:23482703;PMCID:PMC3587478.

Article  PubMed  PubMed Central  Google Scholar 

Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020;158(7):1851–64. https://doi.org/10.1053/j.gastro.2020.01.052. (PMID: 32061595).

Article  CAS  PubMed  Google Scholar 

Ballestri S, Nascimbeni F, Lugari S, Lonardo A, Francica G. A critical appraisal of the use of ultrasound in hepatic steatosis. Expert Rev Gastroenterol Hepatol. 2019;13(7):667–81. https://doi.org/10.1080/17474124.2019.1621164. (PMID: 31104523).

Article  CAS  PubMed  Google Scholar 

Ferraioli G, Soares Monteiro LB. Ultrasound-based techniques for the diagnosis of liver steatosis. World J Gastroenterol. 2019;25(40):6053–62. https://doi.org/10.3748/wjg.v25.i40.6053.PMID:31686762;PMCID:PMC6824276.

Article  PubMed  PubMed Central  Google Scholar 

Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;2(6):33. https://doi.org/10.1186/1471-230X-6-33.PMID:17081293;PMCID:PMC1636651.

Article  Google Scholar 

Siddiqui MS, Yamada G, Vuppalanchi R, et al. NASH clinical research network. Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage. Clin Gastroenterol Hepatol. 2019;17(9):1877-1885.e5. https://doi.org/10.1016/j.cgh.2018.12.031. (PMID: 30616027; PMCID: PMC6609497).

Article  PubMed  PubMed Central  Google Scholar 

Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846–54. https://doi.org/10.1002/hep.21496. (PMID: 17393509).

Article  CAS  PubMed  Google Scholar 

Guarino G, Della Corte T, Strollo F, Gentile S. Policaptil gel retard in adult subjects with the metabolic syndrome: efficacy, safety, and tolerability compared to metformin. Diabetes Metab Syndr. 2021;15(3):901–7. https://doi.org/10.1016/j.dsx.2021.03.032. (PMID: 33906073).

Article  CAS  PubMed  Google Scholar 

Stagi S, Lapi E, Seminara S, et al. Policaptil Gel Retard significantly reduces body mass index and hyperinsulinism and may decrease the risk of type 2 diabetes mellitus (T2DM) in obese children and adolescents with family history of obesity and T2DM. Ital J Pediatr. 2015;15(41):10. https://doi.org/10.1186/s13052-015-0109-7. (PMID: 25774705; PMCID: PMC4339082).

Article  CAS  Google Scholar